91 lines
2.9 KiB
YAML
91 lines
2.9 KiB
YAML
abstract: 'Despite enormous advances in biomedical science, corresponding
|
|
|
|
improvements in health outcomes lag significantly. This is particularly
|
|
|
|
true in the United States, where life expectancy trails far behind that
|
|
|
|
of other high-income countries. In addition, substantial disparities in
|
|
|
|
life expectancy and other health outcomes exist as a function of race,
|
|
|
|
ethnicity, wealth, education, and geographic location. A major
|
|
|
|
reformation of our national system for generating medical evidence-the
|
|
|
|
clinical research enterprise-is needed to facilitate the translation of
|
|
|
|
biomedical research into useful products and interventions. Currently,
|
|
|
|
premarket systems for generating and evaluating evidence work reasonably
|
|
|
|
well, but the postmarket phase is disaggregated and often fails to
|
|
|
|
answer essential questions that must be addressed to provide optimal
|
|
|
|
clinical care and public health interventions for all Americans. Solving
|
|
|
|
these problems will require a focus on three key domains: (1) improving
|
|
|
|
the integration of and access to high-quality data from traditional
|
|
|
|
clinical trials, electronic health records, and personal devices and
|
|
|
|
wearable sensors; (2) restructuring clinical research operations to
|
|
|
|
support and incentivize the involvement of patients and frontline
|
|
|
|
clinicians; and (3) articulating ethical constructs that enable
|
|
|
|
responsible data sharing to support improved implementation. Finally, we
|
|
|
|
must also address the systemic tendency to optimize individual
|
|
|
|
components of the clinical research enterprise without considering the
|
|
|
|
effects on the system as a whole. Overcoming suboptimization by creating
|
|
|
|
incentives for integration and sharing will be essential to achieve more
|
|
|
|
timely and equitable improvement in health outcomes.'
|
|
affiliation: 'Califf, RM (Corresponding Author), US FDA, Off Commissioner, White Oak
|
|
Campus,10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
|
|
|
|
Califf, Robert M., US FDA, Silver Spring, MD USA.
|
|
|
|
Califf, Robert M., US FDA, Off Commissioner, White Oak Campus,10903 New Hampshire
|
|
Ave, Silver Spring, MD 20993 USA.'
|
|
author: Califf, Robert M.
|
|
author-email: commissioner@fda.hhs.gov
|
|
author_list:
|
|
- family: Califf
|
|
given: Robert M.
|
|
da: '2023-09-28'
|
|
doi: 10.1177/17407745221147689
|
|
earlyaccessdate: JAN 2023
|
|
eissn: 1740-7753
|
|
files: []
|
|
issn: 1740-7745
|
|
journal: CLINICAL TRIALS
|
|
keywords: 'Randomized controlled trials; pragmatic clinical trials; clinical trial
|
|
|
|
protocol; evidence-based medicine; precision medicine; healthcare
|
|
|
|
delivery; healthcare systems'
|
|
keywords-plus: HEALTH; CARE
|
|
language: English
|
|
month: FEB
|
|
number: '1'
|
|
number-of-cited-references: '34'
|
|
pages: 3-12
|
|
papis_id: b6d7279b3f827314b57435b7f43880ce
|
|
ref: Califf2023nowis
|
|
times-cited: '5'
|
|
title: Now is the time to fix the evidence generation system
|
|
type: article
|
|
unique-id: WOS:000914687900001
|
|
usage-count-last-180-days: '0'
|
|
usage-count-since-2013: '4'
|
|
volume: '20'
|
|
web-of-science-categories: Medicine, Research \& Experimental
|
|
year: '2023'
|